Keywords: Amgen, Xgeva, Bone metastasis, UK, NICE, Patient access scheme

Amgen's Xgeva gets NICE backing for bone metastasis

Article | 24 October 2012

Print This

New guidance published today (October 24) by the UK’s drugs watchdog the National Institute for Health and Clinical Excellence ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in